Working… Menu

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma (Neo Combi)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01972347
Recruitment Status : Active, not recruiting
First Posted : October 30, 2013
Last Update Posted : March 1, 2021
Information provided by (Responsible Party):
Melanoma Institute Australia